<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988347</url>
  </required_header>
  <id_info>
    <org_study_id>309/2010</org_study_id>
    <nct_id>NCT04988347</nct_id>
  </id_info>
  <brief_title>Spirulina Platensis for PPI Withdrawal</brief_title>
  <acronym>SpAReDPPI</acronym>
  <official_title>The Effect of Spirulina Platensis on Rebound Dyspeptic Symptoms After Discontinuation of Proton Pump Inhibitors: a Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade de Passo Fundo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade de Passo Fundo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Rebound acid hypersecretion after proton pump inhibitors (PPIs) discontinuation&#xD;
      may be accompanied by dyspepsia.&#xD;
&#xD;
      Aim: To assess whether Spirulina platensis, by its anti-inflammatory properties, could&#xD;
      minimize rebound symptoms after PPIs withdrawal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty-five regular users of PPIs entered in a 28-day run-in phase of pantoprazole 40 mg/day,&#xD;
      followed by clinical and endoscopic evaluation. In the absence of large hiatal hernia, peptic&#xD;
      ulcer, or moderate to severe reflux esophagitis, patients stopped PPIs and were randomly&#xD;
      assigned to receive Spirulina (1.6 g/day) or placebo for 2 months, when evaluation was&#xD;
      repeated. Primary outcomes were dyspepsia and typical reflux symptoms (either appearance or&#xD;
      maintenance of symptoms &gt; 50% from baseline). Intention-to-treat analysis was applied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Forty-five regular users of PPIs entered in a 28-day run-in phase of pantoprazole 40 mg/day, followed by clinical and endoscopic evaluation. In the absence of large hiatal hernia, peptic ulcer, or moderate to severe reflux esophagitis, patients stopped PPIs and were randomly assigned to receive Spirulina (1.6 g/day) or placebo for 2 months, when evaluation was repeated. Primary outcomes were dyspepsia and typical reflux symptoms (either appearance or maintenance of symptoms &gt; 50% from baseline). Intention-to-treat analysis was applied.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Capsules containing Spirulina and placebo were identical</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dyspeptic symptoms</measure>
    <time_frame>60 days</time_frame>
    <description>Relapse of dyspeptic symptoms after PPIs cessation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with typical GERD symptoms</measure>
    <time_frame>60 days</time_frame>
    <description>Relapse of typical GERD symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of new endoscopic lesions</measure>
    <time_frame>60 days</time_frame>
    <description>Endoscopic lesions in the esophagus, stomach and duodenum, after PPIs cessation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with microscopic changes in the stomach</measure>
    <time_frame>60 days</time_frame>
    <description>number of participants with new or worsened gastric inflammation after PPIs cessation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with side effects</measure>
    <time_frame>60 days</time_frame>
    <description>Side effects potentially secondary to Spirulina platensis and placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Gastro Esophageal Reflux Disease</condition>
  <condition>Dyspepsia</condition>
  <condition>Rebound Acid Hypersecretion</condition>
  <arm_group>
    <arm_group_label>Spirulina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in capsules, 1 capsule orally each 8 hours, for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Spirulina platensis</intervention_name>
    <description>Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days</description>
    <arm_group_label>Spirulina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Placebo in capsules, 1 capsule orally each 8 hours, for 60 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic use of any PPIs, either original brand or generic&#xD;
&#xD;
          -  Absence of conditions that contraindicate the cessation of PPIs, such as active or&#xD;
             recent peptic ulcer, active or recent upper digestive bleeding, regular use of&#xD;
             salicylates or non-steroidal anti-inflammatory drugs, moderate to severe reflux&#xD;
             esophagitis, and sliding hiatal hernia greater than 3 cm&#xD;
&#xD;
          -  Formal agreement to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncompensated acute and chronic morbidities&#xD;
&#xD;
          -  Gastroesophageal surgery&#xD;
&#xD;
          -  Cognitive deficit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Fornari, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Passo Fundo</affiliation>
  </overall_official>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade de Passo Fundo</investigator_affiliation>
    <investigator_full_name>Fernando Fornari</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastroesophageal reflux disease</keyword>
  <keyword>Dyspepsia</keyword>
  <keyword>Proton Pump Inhibitors</keyword>
  <keyword>Spirulina platensis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

